Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ITT-PMS; PMSIT
- 10 Oct 2018 Results published in the Neurology
- 18 Nov 2016 Status changed from recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2016, as reported by ClinicalTrials.gov record.